Indications and uses
Provides moderate protection against sunburn
stila illuminate and shine
- Manufacturer
- Stila Styles, LLC | GORDON LABORATORIES, INC.
- Effective date
- 2013-11-25
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-05-31 22:37:45
Label at a glance#
Productstila illuminate and shine
Active ingredientOctinoxate, Avobenzone, Octisalate
Label structure8 sections
Dosage and administration
Apply to clean skin with fingerstips.
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
illuminating tinted moisturizer - shade 01
Drug Facts
OTC - ACTIVE INGREDIENT SECTION
OTC - PURPOSE SECTION
| Active Ingredients | Purpose |
|---|---|
| Octinoxate 7.5 % | sunscreen |
| Avobenzone 3% | sunscreen |
| Octisalate 2% | sunscreen |
Uses
Provides moderate protection against sunburn
Warnings
For external use only.
The sun may cause sunburn, premature aging of the skin, and skin cancer. Avoiding the sun, wearing protective clothing, and regular use of sunscreens over the years may reduce the chance of harmful effects.
When using this product
- Keep out of eyes.
Stop use and ask a doctor if
Irritation occurs.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children
Directions
Apply to clean skin with fingerstips.
Inactive Ingredients
water (aqua), diethylhexyl carbonate, cyclopentasiloxane, ethylhexyl stearate, diisostearoyl polyglyceryl-3 dimer dilinoleate, glycerin, prunus amygdalus dulcis (sweet almond) oil, alumina, magnesium sulfate, microcrystalline wax/cera microcristallina, cetyl dimethicone, cyclohexasiloxane, hydrogenated castor oil, phenoxyethanol, chlorphenesin, cetyl peg/ppg10/1 dimethicone, polyglyceryl-4 isostearate, hexyl laurate, benzoic acid, butylene glycol, sorbic acid, isopropyl titanium triisostearate, tin oxide may contain (+/-) mica, titanium dioxide (ci77981), iron oxides (ci77491, ci77492, ci77499) <iln c71055>
SPL UNCLASSIFIED SECTION
dist. by © stila styles, llc • los angeles, ca 90027
PRINCIPAL DISPLAY PANEL - Kit Label
stila
illuminate and shine
this exclusive set contains stila's best-selling illuminating tinted moisturizer in shade 01,
one step primecolor in kitten and illuminating finishing powder in gold
stilacosmetics.com
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| c6f86816-7da6-43ea-8c25-ac9758311cc5 | Product name | 1 | 20220118 |
| 252e11b6-1a9a-4283-a242-df2c129c496d | Product name | 3 | 20170717 |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 76049-620-01 | 2019-11-27 | C162847 | 48780-1 | 9855e2a2-449d-60a7-e053-dbdaa90a05bd | stila illuminate and shine |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 76049-620-01 | stila illuminate and shine | 1 in 1 PACKAGE, COMBINATION | KIT | 1 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Avobenzone | ACTIVE INGREDIENT | G63QQF2NOX | 1 | |
| Octinoxate | ACTIVE INGREDIENT | 4Y5P7MUD51 | 1 | |
| Octisalate | ACTIVE INGREDIENT | 4X49Y0596W | 1 | |
| Avobenzone | ACTIVE MOIETY | G63QQF2NOX | 1 | |
| Octinoxate | ACTIVE MOIETY | 4Y5P7MUD51 | 1 | |
| Octisalate | ACTIVE MOIETY | 4X49Y0596W | 1 | |
| almond oil | INACTIVE INGREDIENT | 66YXD4DKO9 | 1 | |
| aluminum oxide | INACTIVE INGREDIENT | LMI26O6933 | 1 | |
| benzoic acid | INACTIVE INGREDIENT | 8SKN0B0MIM | 1 | |
| butylene glycol | INACTIVE INGREDIENT | 3XUS85K0RA | 1 | |
| chlorphenesin | INACTIVE INGREDIENT | I670DAL4SZ | 1 | |
| cyclomethicone 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 1 | |
| cyclomethicone 6 | INACTIVE INGREDIENT | XHK3U310BA | 1 | |
| diethylhexyl carbonate | INACTIVE INGREDIENT | YCD50O0Z6L | 1 | |
| diisostearoyl polyglyceryl-3 dimer dilinoleate | INACTIVE INGREDIENT | G3232Z5S2O | 1 | |
| ethylhexyl stearate | INACTIVE INGREDIENT | EG3PA2K3K5 | 1 | |
| ferric oxide red | INACTIVE INGREDIENT | 1K09F3G675 | 1 | |
| ferric oxide yellow | INACTIVE INGREDIENT | EX438O2MRT | 1 | |
| ferrosoferric oxide | INACTIVE INGREDIENT | XM0M87F357 | 1 | |
| glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| hexyl laurate | INACTIVE INGREDIENT | 4CG9F9W01Q | 1 | |
| hydrogenated castor oil | INACTIVE INGREDIENT | ZF94AP8MEY | 1 | |
| isopropyl titanium triisostearate | INACTIVE INGREDIENT | 949E3KBJ1I | 1 | |
| magnesium sulfate | INACTIVE INGREDIENT | DE08037SAB | 1 | |
| mica | INACTIVE INGREDIENT | V8A1AW0880 | 1 | |
| microcrystalline wax | INACTIVE INGREDIENT | XOF597Q3KY | 1 | |
| phenoxyethanol | INACTIVE INGREDIENT | HIE492ZZ3T | 1 | |
| polyglyceryl-4 isostearate | INACTIVE INGREDIENT | 820DPX33S7 | 1 | |
| sorbic acid | INACTIVE INGREDIENT | X045WJ989B | 1 | |
| stannic oxide | INACTIVE INGREDIENT | KM7N50LOS6 | 1 | |
| titanium dioxide | INACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- stila illuminate and shine
- Octinoxate, Avobenzoate, and Octisalate
- illuminated tinted moisturizer shade 01
- Octinoxate, Avobenzone, and Octisalate
- Octinoxate
- Avobenzone
- Octisalate
- water
- diethylhexyl carbonate
- cyclomethicone 5
- ethylhexyl stearate
- diisostearoyl polyglyceryl-3 dimer dilinoleate
- glycerin
- almond oil
- aluminum oxide
- magnesium sulfate
- microcrystalline wax
- cyclomethicone 6
- hydrogenated castor oil
- phenoxyethanol
- chlorphenesin
- polyglyceryl-4 isostearate
- hexyl laurate
- benzoic acid
- butylene glycol
- sorbic acid
- isopropyl titanium triisostearate
- stannic oxide
- mica
- titanium dioxide
- ferric oxide red
- ferric oxide yellow
- ferrosoferric oxide
- one step primecolor kitten
- Inert
- dimethicone
- isododecane
- hydrogenated didecene
- silicon dioxide
- silica dimethyl silylate
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 76049-620 | 76049-620-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | SUSPENSION / ORAL | 113 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| ferric oxide red | FERRIC OXIDE RED | 1K09F3G675 | SUSPENSION, EXTENDED RELEASE / ORAL | 2.7 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| benzoic acid | BENZOIC ACID | 8SKN0B0MIM | GEL / RECTAL | 11 mg | ||
| magnesium sulfate | MAGNESIUM SULFATE | DE08037SAB | CAPSULE / ORAL | NA | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, EXTENDED RELEASE / ORAL | 90 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | PASTE, DENTIFRICE / DENTAL | 0.4 %w/w | ||
| sorbic acid | SORBIC ACID | X045WJ989B | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 1 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | PASTE / ORAL | 3822 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 11 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | GUM, CHEWING / BUCCAL | 182 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / ORAL | 2 mg | ||
| ferrosoferric oxide | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET, EXTENDED RELEASE / ORAL | 8 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| benzoic acid | BENZOIC ACID | 8SKN0B0MIM | TABLET, FILM COATED / ORAL | NA | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, DELAYED RELEASE / ORAL | 66 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, CHEWABLE / ORAL | 14 mg | ||
| benzoic acid | BENZOIC ACID | 8SKN0B0MIM | SUSPENSION / RECTAL | 0.1 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| ferric oxide red | FERRIC OXIDE RED | 1K09F3G675 | LOTION / TOPICAL | NA | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| hydrogenated castor oil | HYDROGENATED CASTOR OIL | ZF94AP8MEY | TABLET, EXTENDED RELEASE / ORAL | 393 mg | ||
| microcrystalline wax | MICROCRYSTALLINE WAX | XOF597Q3KY | OINTMENT / TOPICAL | 3575 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / SUBCUTANEOUS | 15 %w/v | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | DROPS / ORAL | NA | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER, FOR SUSPENSION / ORAL | 297 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | CLOTH / TOPICAL | 0.05 mg/mg | ||
| phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL / TOPICAL | 1.05 %w/w | ||
| sorbic acid | SORBIC ACID | X045WJ989B | TABLET, COATED / ORAL | 1 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION, CONCENTRATE / ORAL | 200 mg/1ml | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CREAM / TOPICAL | 80 mg | ||
| sorbic acid | SORBIC ACID | X045WJ989B | TABLET, FILM COATED / ORAL | 5 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | CAPSULE, EXTENDED RELEASE / ORAL | 7 mg | ||
| phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | GEL / TOPICAL | 14 mg | ||
| benzoic acid | BENZOIC ACID | 8SKN0B0MIM | TABLET, COATED / ORAL | NA | ||
| ferrosoferric oxide | FERROSOFERRIC OXIDE | XM0M87F357 | CAPSULE, COATED / ORAL | 0.11 mg | ||
| microcrystalline wax | MICROCRYSTALLINE WAX | XOF597Q3KY | CAPSULE, EXTENDED RELEASE / ORAL | 6 mg | ||
| benzoic acid | BENZOIC ACID | 8SKN0B0MIM | INJECTION / INTRAVENOUS | 5 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE / ORAL | 55 mg | ||
| benzoic acid | BENZOIC ACID | 8SKN0B0MIM | ELIXIR / ORAL | 90 mg | ||
| benzoic acid | BENZOIC ACID | 8SKN0B0MIM | AEROSOL, FOAM / TOPICAL | 1 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | SUPPOSITORY / VAGINAL | NA | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | OINTMENT / TOPICAL | 5 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 2 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| ferric oxide red | FERRIC OXIDE RED | 1K09F3G675 | TABLET, FILM COATED / ORAL | 3 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | GEL / TOPICAL | 0.06 %w/w | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | SYSTEM / TOPICAL | 420 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| ferrosoferric oxide | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET, COATED / ORAL | NA | ||
| benzoic acid | BENZOIC ACID | 8SKN0B0MIM | SOLUTION / IRRIGATION | 0.02 %w/v | ||
| benzoic acid | BENZOIC ACID | 8SKN0B0MIM | LOTION / TOPICAL | 0.2 %w/w | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | CAPSULE, COATED / ORAL | 0.01 mg | ||
| benzoic acid | BENZOIC ACID | 8SKN0B0MIM | MOUTHWASH / BUCCAL | NA |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 2b674434-a7bf-4d46-88b9-29cfbc5cfdf7 | aaa27998-0db4-4884-80f7-43c9bc6815a9 | 2013-11-25 | Warnings | 2b674434-a7bf-4d46-88b9-29cfbc5cfdf7 aaa27998-0db4-4884-80f7-43c9bc6815a9 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.